Sfoglia per AUTORE
DANCHAIVIJITR P
Collezione AOU San Luigi di Orbassano
Items : 2
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.
2024
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Leighl NB; Akamatsu H; Lim SM; Cheng Y; Minchom AR; Marmarelis ME; Sanborn RE; Chih-Hsin Yang J; Liu B; John T; Massutí B; Spira AI; Lee SH; Wang J; Li J; Liu C; Novello S; Kondo M; Tamiya M; Korbenfeld E; Moskovitz M; Han JY; Alexander M; Joshi R; Felip E; Voon PJ; Danchaivijitr P; Hsu PC; Silva Melo Cruz FJ; et alii...
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. in Nature medicine / Nat Med. 2022 Sep;28(9):1831-1839. doi: 10.1038/s41591-022-01933-w. Epub 2022 Aug 22.
2022
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Peters S; Dziadziuszko R; Morabito A; Felip E; Gadgeel SM; Cheema P; Cobo M; Andric Z; Barrios CH; Yamaguchi M; Dansin E; Danchaivijitr P; Johnson M; Novello S; Mathisen MS; Shagan SM; Schleifman E; Wang J; Yan M; Mocci S; Voong D; Fabrizio DA; Shames DS; Riehl T; Gandara DR; Mok T;